Roche acquires PathAI for up to $1.05 billion to strengthen AI diagnostics and digital pathology

Roche To Acquire PathAI In Up To $1.05 Billion Deal To Expand Digital Pathology Push - Roche Holding (OTC

Roche (OTC:RHHBY) said Wednesday it will acquire U.S.-based digital pathology and AI company PathAI in a deal worth up to $1.05 billion, including milestone payments. The acquisition will expand Roche's digital pathology and AI diagnostics capabilities. PathAI is set to join its diagnostics division once the deal closes later this year. Deal Builds On Existing Partnership Under the agreement, Roche will pay $750 million upfront, with additional milestone payments of up to $300 million. Roche and PathAI first partnered in 2021 and expanded their collaboration in 2024 to develop AI-enabled companion diagnostic algorithms. The company said the acquisition will enhance its digital pathology portfolio by integrating PathAI's Image Management System, AISight, with Roche's oncology diagnostics platforms. Digital pathology converts tissue samples on slides into high-resolution digital images, enabling pathologists to use AI-powered tools to support diagnostic workflows and potentially speed up patient results. Focus On Precision Medicine And Biomarker Discovery PathAI's AI-driven tools also support clinical trials and translational research. Roche said these capabilities will complement its companion diagnostics expertise and strengthen its services for biopharma companies. The combined technologies are expected to support the discovery of new biomarkers, potential drug targets, and additional diagnostic tools, helping accelerate the shift toward personalized healthcare. Photo by OleksSH via Shutterstock Market News and Data brought to you by Benzinga APIs To add Benzinga News as your preferred source on Google, click here.

Roche to Buy PathAI for Up to $1.05 Billion to Bolster AI Diagnostics Tools

Roche Holding said it agreed to buy PathAI for up to $1.05 billion in a deal that seeks to bolster the artificial-intelligence offerings of its diagnostics division. The Swiss pharmaceutical group said Thursday that the acquisition of U.S.-based PathAI would build on a partnership between the two companies formed in 2021 and take in-house an AI platform that aims to facilitate diagnostic workflows and help accelerate clinical-therapy development. Under the deal, Roche agreed to pay $750 million upfront, with up to $300 million in additional payments subject to targets, it said. The deal is expected to close in the second half of the year. Roche said that it intends to scale globally PathAI's technology for pathology laboratories and the biopharma industry. The company expects to combine PathAI's offerings with its own in order to drive laboratory efficiency and foster the discovery of potential drug targets and new diagnostic tools.